// App-Quantinova.ai

CTNI-67 : EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET

Researchers

Presenter

  • Sbastien Perreault

Principal Investigators

  • Alexander Drilon

  • Birgit Geoerger

  • Valentina Boni

  • Julia Chisholm

  • Steven G Dubois

  • Juneko E Grilley-Olson

  • David S Hong

  • Antoine Italiano

  • HyoungJin Kang

  • Karsten Nysom

  • Ingrid ra

  • Cormac Owens

  • Johannes H Schulte

  • Makoto Tahara

  • David Ziegler

  • Benjamin Ellezam

  • John A Reeves

  • Marc Fellous

  • Esther De La Cuesta

  • Theodore W Laetsch

  • Cornelis M van Tilburg

Medical Centers

  • CHU Sainte-Justine, Montreal, QC, Canada

  • Institut Curie, Paris Saclay University, Paris, France

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Gustave Roussy Department of Pediatric and Adolescent Oncology ,Universite Paris-Sud, Universite Paris-Saclay, Villejuif, France

  • START Madrid, CIOCC, Madrid, Spain

  • Children and Young Peoples Unit, Royal Marsden Hospital, Surrey, United Kingdom

  • Dana-Farber/Boston Childrens Hospital Cancer and Blood Disorders Center, Boston, MA

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France

  • Seoul National University Children's Hospital, Seoul, Republic of Korea

  • Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark

  • Department of Pediatric Oncology, Skåne University Hospital, Lund & Karolinska University Hospital, Lund, Sweden

  • Department of Haematology, Our Ladys Childrens Hospital, Dublin, Ireland

  • Department of Pediatric Oncology/Hematology, Charite Medical University Berlin, Berlin, Germany.

  • National Cancer Center, EPOC, Chiba, Japan

  • Sydney Adventist Hospital, Sydney, Australia

  • Sydney Childrens Hospital, Sydney, New South Wales, Australia

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • University of Texas Southwestern Medical Center and Children's Health, Dallas, TX

  • Hopp Childrens Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany

Locations

  • Canada

  • France

  • United States

  • Spain

  • United Kingdom

  • Republic of South Korea

  • Denmark

  • Sweden

  • Ireland

  • Germany

  • Japan

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Neurotrophic tropomyosin receptor kinase

Drug/Treatment

  • Larotrectinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02637687

  • NCT02576431

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved